Lifecore (LFCR) Q4 Revenue Beats 3%

Lifecore Biomedical (NASDAQ:LFCR), a contract development and manufacturing company focused on sterile injectable pharmaceuticals and hyaluronic acid (HA) products, reported fiscal fourth-quarter 2025 results on August 7, 2025. The company reported GAAP revenue of $36.4 million in Q4 FY2025, exceeding the analyst estimate of $35.4 million (GAAP), and narrowed its GAAP loss per share to $(0.06), beating the forecast $(0.10) GAAP loss. Despite revenue being down from the prior year, Lifecore showed improvement in operational efficiency and business development activity, closing the period with better-than-expected financials. However, Gross profit (GAAP) and adjusted EBITDA (non-GAAP) both declined year over year. Overall, the quarter delivered positive surprises on GAAP revenue and GAAP earnings, but margin pressures and ongoing net losses remain notable issues. Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q3 2025 earnings report. Lifecore Biomedical operates as a contract development and manufacturing organization (CDMO), delivering sterile injectable drugs and hyaluronic acid-based products to pharmaceutical and biotechnology clients. Its vertically integrated platform covers everything from producing HA raw materials to aseptic filling of finished products, supplying both drug makers and medical device companies.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool